From obesity to diabetes: Why, when and who?

Acta Clinica Belgica

Volumn 55, Issue 1, 2000, Pages 9-15

  Scheen, A J ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Diabetes mellitus; Insulin resistance; Insulin secretion; Obesity; Prevention; Treatment

Indexed keywords

FATTY ACID; GLUCOSE; INSULIN;

ADIPOSE TISSUE; BLOOD; DISEASE COURSE; EPIDEMIOLOGY; HUMAN; INSULIN RESISTANCE; LIPID METABOLISM; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET; PATHOLOGY; REVIEW; RISK FACTOR; SECRETION;

ADIPOSE TISSUE; CAUSALITY; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; FATTY ACIDS, NONESTERIFIED; GLUCOSE; HUMANS; INSULIN; INSULIN RESISTANCE; ISLETS OF LANGERHANS; LIPID METABOLISM; OBESITY; RISK FACTORS;

EID: 0033656405     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: 10.1080/17843286.2000.11754266     Document Type: Article

References (37)

1. Scheen AJ, Lefèbvre PJ. Pathophysiology of Type 2 diabetes. In: Kuhlmann J, Puls W, eds. Handbook of Experimental Pharmacology, Oral Antidiabetics. Berlin: Springer Verlag, 1996, 7-42.
2. DeFronzo RA. Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes. Diabetes Rev. 1997; 5: 177-269.
3. Willett WC, Dietz WH, Colditz GA. Guidelines for healthy weight. N Engl J Med. 1999; 341: 427-34.
4. Björntorp P. Abdominal obesity and the development of non-insulin-dependent diabetes mellitus. Diab Metab Rev. 1988; 4: 615-22.
5. Wannamethee SG, Shaper AG. Weight change and duration of overweight and obesity in the incidence of type 2 diabetes. Diabetes Care. 1999; 22: 1266-72.
6. Scheen AJ. Aggressive weight reduction treatment in the management of type 2 diabetes. Diab Metab. 1998; 23: 116-23.
7. Scheen AJ, Lefèbvre PJ. Management of the obese diabetic patient. Diabetes Rev. 1999; 7: 77-93.
8. Yki-Järvinen H. Role of insulin resistance in the pathogenesis of NIDDM. Diabetologia. 1995; 38: 1378-88.
9. Scheen AJ. From obesity to diabetes. Acta Clin Belg. 1992; 47. Suppl 14: 30-6.
10. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes. 1997; 45: 3-10.
11. 13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents. Diabetes. 1999; 48: 1600-6.
12. Scheen AJ, Castillo MJ, Paquot N, Lefèbvre PJ. How to measure insulin action in vivo. Diabetes Metab Rev. 1994; 10: 151-88.
13. Scheen AJ, Paquot N, Letiexhe MR, Paolisso G, Castillo MJ, Lefèbvre PJ. Glucose metabolism in obese subjects: lessons from OGTT, IVGTT and clamp studies. Int J Obesity. 1995; 19 (Suppl 3): S14-S20.
14. Scheen AJ, Lefèbvre PJ. Assessment of insulin resistance in vivo. Application to the study of type 2 diabetes. Horm Res. 1992; 38: 19-27.
15. Hotamisligil GS, Spiegelman BM. Tumor necrosis factor-α: A key component of the obesity-diabetes link. Diabetes. 1994; 43: 1271-8.
16. Scheen AJ, Castillo MJ, Paquot N, Lefèbvre PJ. No effect of neutralization of TNF-α on insulin-mediated glucose disposal in obese insulin-resistant subjects (Abstract). Diabetologia. 1996; 39 (Suppl. 1): A153.
17. Paquot N, Scheen AJ, Lefèbvre PJ. Contribution hémodynamique à l'insulinorésistance: du concept physiopathologique aux perspectives thérapeutiques. Med Hyg. 1995; 53: 1633-7.
18. Polonsky KS, Sturis J, Bell GI. Non-insulin-dependent diabetes mellitus: a genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med. 1996; 334: 777-84.
19. Hales CN, Desai M, Ozanne SE. The thrifty phenotype hypothesis: how does it look after 5 years? Diabetic Med. 1997; 14: 189-95.
20. Yki-Järvinen H. Glucose toxicity. Endocr Rev. 1992; 15: 415-31.
21. Unger RH. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. Diabetes. 1995; 44: 863-70.
22. McGarry, JD, Dobbins RL. Fatty acids, lipotoxicity and insulin secretion. Diabetologia. 1999; 42: 128-38.
23. Leahy JL. Impaired ß-cell function with chronic hyperglycemia: "overworked ß-cell" hypothesis. Diabetes Wer. 1996; 4: 298-319.
24. Golay A, Felber JP. Evolution from obesity to diabetes. Diab Metab. 1994; 20:3-14.
25. Kahn CR. Banting Lecture. Insulin action, diabetogenes, and the cause of type II diabetes. Diabetes. 1994; 43: 1066-84.
26. Lev-Ran A. Thrifty genotype: how applicable is it to obesity and type 2 diabetes? Diabetes Rev. 1999; 7: 1-22.
27. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report on the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997; 20: 1183-97.
28. Larsson B. Obesity and propective risk of associated diseases. In: Vague J, Björntorp P, Guy-Grand B, Rebuffé-Scrive M, Vague P, eds. Metabolic Complications of the Human Obesities. Amsterdam, Elsevier, 1985: 21-9.
29. Scheen AJ. Intérêts et limites de la diète protéique chez le patient obèse diabétique de type 2. Ann Endocrinol. 1999; 60: 103-10.
30. Scheen AJ. Anti-obesity drugs in the treatment of NIDDM. Int Diabetes Monitor. 1997; 9: 1-8.
31. Scheen AJ, Luyckx FH, Desaive C. Lefèbvre PJ. Severe/extreme obesity: a medical disease requiring a surgical treatment:? Acta Clin Belg. 1999; 54: 154-61.
32. Letiexhe MR, Scheen AJ, Gérard PL, Desaive C, Lefèbvre PJ. Post-gastroplasty recovery of ideal body weight normalizes glucose and insulin metabolism in obese women. J Clin Endocrinol Metab. 1995; 80: 393-9.
33. Luyckx FH, Scheen AJ, Desaive C, Dewé W, Gielen JE, Lefèbvre PJ. Effects of gastroplasty on body weight and related biological abnormalities in morbid obesity. Diab Metab. 1998; 24: 355-61.
34. Scheen AJ. Insulin resistance syndrome and atherosclerotic cardiovascular disease. Acta Clin Belg. 1996; 51: 65-9.
35. Brown SA, Upchurch S, Anding R, Winter M, Ramirez G. Promoting weight loss in type II diabetes. Diabetes Care. 1996; 19: 613-24.
36. Maggio CA, Pi-Sunyer FX. The prevention and treatment of obesity. Application to type 2 diabetes. Diabetes Care. 1997; 20:1744-66.
37. Scheen AJ. L'"épidémie" des maladies métaboliques, un problème majeur de santé publique. Rev Med Liege. 1999; 54: 87-94.